Kadmon Holdings Inc (NYSE:KDMN) Expected to Post Quarterly Sales of $590,000.00

Brokerages expect that Kadmon Holdings Inc (NYSE:KDMN) will post sales of $590,000.00 for the current quarter, Zacks reports. Four analysts have provided estimates for Kadmon’s earnings, with estimates ranging from $230,000.00 to $740,000.00. Kadmon posted sales of $230,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 156.5%. The firm is scheduled to announce its next quarterly earnings results on Monday, August 3rd.

According to Zacks, analysts expect that Kadmon will report full year sales of $7.25 million for the current financial year, with estimates ranging from $3.20 million to $9.51 million. For the next fiscal year, analysts anticipate that the firm will report sales of $189.10 million, with estimates ranging from $25.16 million to $668.25 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Kadmon.

Kadmon (NYSE:KDMN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $6.74 million for the quarter, compared to the consensus estimate of $0.38 million. Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%.

A number of research firms have recently commented on KDMN. Raymond James began coverage on shares of Kadmon in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $7.00 price target on the stock. ValuEngine upgraded shares of Kadmon from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a research note on Sunday. Oppenheimer restated a “buy” rating and issued a $8.00 price objective on shares of Kadmon in a research note on Thursday, May 7th. Finally, Zacks Investment Research upgraded shares of Kadmon from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research note on Thursday, June 4th. Seven equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $10.88.

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its stake in Kadmon by 208.5% during the first quarter. BNP Paribas Arbitrage SA now owns 56,524 shares of the company’s stock worth $237,000 after buying an additional 38,204 shares in the last quarter. EAM Investors LLC acquired a new stake in Kadmon during the fourth quarter worth $1,563,000. UBS Group AG boosted its stake in Kadmon by 39.8% during the first quarter. UBS Group AG now owns 282,203 shares of the company’s stock worth $1,182,000 after buying an additional 80,332 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Kadmon by 767.5% during the first quarter. JPMorgan Chase & Co. now owns 442,635 shares of the company’s stock worth $1,855,000 after buying an additional 391,612 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Kadmon during the fourth quarter worth $289,000. Hedge funds and other institutional investors own 85.64% of the company’s stock.

Shares of NYSE:KDMN traded down $0.04 during trading on Friday, reaching $5.14. The stock had a trading volume of 79,709 shares, compared to its average volume of 2,662,520. Kadmon has a 52 week low of $1.82 and a 52 week high of $5.50. The firm has a market capitalization of $844.96 million, a price-to-earnings ratio of -7.37 and a beta of 1.47. The company has a quick ratio of 6.40, a current ratio of 6.42 and a debt-to-equity ratio of 0.20. The stock has a fifty day simple moving average of $4.58 and a two-hundred day simple moving average of $4.42.

About Kadmon

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Recommended Story: Yield Curve

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.